| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/31/2007 | WO2007061360A2 Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides |
| 05/31/2007 | WO2007061243A1 Composition comprising the extract of cassiae semen for treating or preventing cognitive dysfunction |
| 05/31/2007 | WO2007061114A1 Pharmaceutical composition for prevention or treatment of neurogenic pain |
| 05/31/2007 | WO2007061074A1 Novel bisboron compound |
| 05/31/2007 | WO2007060974A1 Pharmaceutical for use in the treatment of ureterolithiasis |
| 05/31/2007 | WO2007060899A1 Application of actin-binding protein to disease associated with cell motility |
| 05/31/2007 | WO2007060886A1 Therapeutic agent for neurodegenerative disease |
| 05/31/2007 | WO2007060821A1 Bicyclic cinnamide compound |
| 05/31/2007 | WO2007060810A1 Morpholine type cinnamide compound |
| 05/31/2007 | WO2007060540A1 Stable dosage forms of an antidepressant |
| 05/31/2007 | WO2007060526A1 Substituted azacycloalkanes useful for treating cns conditions |
| 05/31/2007 | WO2007060484A1 Azetidine derivatives as glyt1 inhibitors |
| 05/31/2007 | WO2007060132A1 N-hydroxyamide derivatives and use thereof |
| 05/31/2007 | WO2007060112A1 Salicylic acid derivatives |
| 05/31/2007 | WO2007060027A1 Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor |
| 05/31/2007 | WO2007059762A1 Combination preparations containing physiological cell membrane constituents including phosphatidylserine, choline and a pyrimidine nucleoside/nucleotide |
| 05/31/2007 | WO2007059574A1 A molecule and chimeric molecules thereof |
| 05/31/2007 | WO2007042669A3 Derivatives of 4-amino-quinazoline, preparation method thereof and use of same in therapeutics |
| 05/31/2007 | WO2007042660A3 Substituted 1-amino-phthalzine derivatives, preparation and therapeutic use thereof |
| 05/31/2007 | WO2007040438A3 Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders |
| 05/31/2007 | WO2007039740A3 Preparation and use of tetrahydropyrrolo [3, 2-c] pyridin-4-one derivatives for treatment of obesity, psychiatric and neurological disorders |
| 05/31/2007 | WO2007038677A3 Methods for preparation of ladostigil tartrate crystalline form a1 |
| 05/31/2007 | WO2007037554A9 Adsorbent for advanced glycation endproducts |
| 05/31/2007 | WO2007037543A9 Biarylamide derivative |
| 05/31/2007 | WO2007036718A3 Compounds which have activity at m1 receptor and their uses in medicine |
| 05/31/2007 | WO2007036033A8 Oligodendrocyte precursor cell proliferation regulated by prolactin |
| 05/31/2007 | WO2007030618A3 Bicyclic derivatives as modulators of voltage gated ion channels |
| 05/31/2007 | WO2007030438A3 Aminopurine derivatives for treating neurodegenerative diseases |
| 05/31/2007 | WO2007022964A3 Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors |
| 05/31/2007 | WO2007020672A3 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease |
| 05/31/2007 | WO2007016160A3 Svct2 transporters expressed in blood brain barrier cells |
| 05/31/2007 | WO2007012968A3 Stable dosage form of an antidepressant |
| 05/31/2007 | WO2006136419B1 Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases |
| 05/31/2007 | WO2006127900A3 Tl1a in the treatment of disease |
| 05/31/2007 | WO2006116862A9 Method for inhibiting er stress-induced apoptosis |
| 05/31/2007 | WO2006114790A3 Polar lipid mixtures, their preparation and uses |
| 05/31/2007 | WO2006110496A3 Activation of sodium potassium atpase |
| 05/31/2007 | WO2006073715A3 Use of selected compounds for protection of neurones and oligodendrocytes in the treatment of multiple sclerosis |
| 05/31/2007 | US20070124837 Desaturase genes, enzymes encoded thereby, and uses thereof |
| 05/31/2007 | US20070123705 Alkylation; serotonin receptor antagonists; depression, obsessive compulsive disorders, panic disorder, generalized anxiety disorder, social anxiety, sexual dysfunction, bulimia, obesity, addictive disorder |
| 05/31/2007 | US20070123570 Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| 05/31/2007 | US20070123532 Piperazine derivatives |
| 05/31/2007 | US20070123530 e.g. (2-chloropyrimidin-4-yl)-(4-ethyl-3H-thiazol-2ylidene)-acetonitrile,[4-(4-chlorophenyl)-1,3-thiazol-2(3H)-ylidene](2-chloropyrimidin-4-yl)acetonitrile; Jun N-terminal kinase and Glycogen Synthase Kinase 3 inhibitor; antidiabetic, antiinflammatory, anticarcinogenic agent; neurodegenerative diseases |
| 05/31/2007 | US20070123529 Substituted biphenyl compounds |
| 05/31/2007 | US20070123503 Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
| 05/31/2007 | US20070122504 Grape seed extract having neuronal cell-protection activity and the composition comprising the same for preventing and treating degenerative brain disease |
| 05/31/2007 | US20070122475 Taste masking composition |
| 05/31/2007 | US20070122452 Fat composition |
| 05/31/2007 | US20070122381 Method for regulating neuron development and maintenance |
| 05/31/2007 | US20070122348 For preventing oral abuse of an oral opioid formulation; provides a negative, "aversive" experience when a large amount of the opioid, e.g., about 2-3 times the usually prescribed dose, is taken by or administered to a physically dependent subject |
| 05/31/2007 | DE69133083C5 Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten Treatment and prevention mediated by elevated lyso-PAF mirror mental disorders with PAF antagonists |
| 05/31/2007 | DE102005056558A1 Kombinationspräparate enthaltend physiologische Zellmembran-Bestandteile Combination products containing physiological cell membrane components |
| 05/31/2007 | CA2631121A1 Use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells |
| 05/31/2007 | CA2631017A1 Bisboron compounds for use as intracellular calcium concentration increase inhibitors |
| 05/31/2007 | CA2630922A1 Treatment of neurodegenerative disorders |
| 05/31/2007 | CA2630818A1 Pharmaceutical composition for prevention or treatment of neurogenic pain |
| 05/31/2007 | CA2630805A1 Salicylic acid derivatives |
| 05/31/2007 | CA2630655A1 Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor |
| 05/31/2007 | CA2630551A1 N-hydroxyamide derivatives and use thereof |
| 05/31/2007 | CA2630459A1 Substituted azacycloalkanes useful for treating cns conditions |
| 05/31/2007 | CA2630039A1 Azetidine derivatives as glyt1 inhibitors |
| 05/31/2007 | CA2629800A1 Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity |
| 05/31/2007 | CA2629745A1 Morpholine type cinnamide compound |
| 05/31/2007 | CA2629512A1 Bicyclic cinnamide compound and prophylactic or therapeutic uses thereof |
| 05/31/2007 | CA2628476A1 Pharmaceutical for use in the treatment of ureterolithiasis |
| 05/30/2007 | EP1790725A2 Proteins named after FCTRX and nucleic acids encoding same |
| 05/30/2007 | EP1790687A2 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 05/30/2007 | EP1790652A1 Polycyclic guanine phosphodiesterase V inhibitors |
| 05/30/2007 | EP1790648A1 Use of procyanidin B2 for the preparation of a medicament for the treatment of amyloid and synuclein diseases |
| 05/30/2007 | EP1790646A1 Isoquinoline und benzo[h]isoquinoline derivatives, their preparation and their therapeutical application as antagonists of histamine H3 receptor . |
| 05/30/2007 | EP1790644A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 05/30/2007 | EP1790641A1 Triazole derivative or salt thereof |
| 05/30/2007 | EP1790353A1 Combined use of a GLP-1 compound and a modulator of diabetic late complications |
| 05/30/2007 | EP1790352A1 Use of botulinum toxin type B for the manufacture of a medicament for reducing pain associated with a muscle disorder |
| 05/30/2007 | EP1790345A1 Triazin beta-secretase inhibitors |
| 05/30/2007 | EP1790341A1 Medicine having analgesic effects |
| 05/30/2007 | EP1790337A2 Methods and compounds for treating depression and other disorders |
| 05/30/2007 | EP1789417A1 AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS |
| 05/30/2007 | EP1789414A1 2-morpholino-4-pyrimidone compound |
| 05/30/2007 | EP1789410A1 Methylene dipiperidine derivatives |
| 05/30/2007 | EP1789404A2 Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
| 05/30/2007 | EP1789398A1 2-amino-quinazoline derivatives useful as inhibitors of b-secretase (bace) |
| 05/30/2007 | EP1789386A1 Substituted indole compounds, their preparation and use in medicaments |
| 05/30/2007 | EP1789380A1 Amino adamantane derivatives, methods for the production and use thereof |
| 05/30/2007 | EP1789086A2 Extended treatment of multiple sclerosis |
| 05/30/2007 | EP1789079A1 Enzyme inhibitors and uses thereof |
| 05/30/2007 | EP1789078A1 Pulmonary delivery of a nerve agent neutralizing enzyme |
| 05/30/2007 | EP1789077A2 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
| 05/30/2007 | EP1789070A2 Taj in neuronal function |
| 05/30/2007 | EP1789057A2 Neuroprotective effect of solubilized udca in focal ischemic model |
| 05/30/2007 | EP1789056A1 Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts |
| 05/30/2007 | EP1789050A1 Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| 05/30/2007 | EP1789048A1 Method for the treatment of attention deficit hyperactivity disorder |
| 05/30/2007 | EP1789033A2 Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders |
| 05/30/2007 | EP1789028A2 Compositions for treating nociceptive pain |
| 05/30/2007 | EP1789021A2 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| 05/30/2007 | EP1673372B1 Non-amide nonanes |
| 05/30/2007 | EP1496924A4 Treatment of gastroparesis |
| 05/30/2007 | EP1417211B1 Natural phospholipids of marine origin containing flavonoids and polyunsaturated phospholipids and their uses |
| 05/30/2007 | EP1392291B1 Tripeptidyl peptidase inhibitors |